Atara biotherapeutics announces $31 million royalty interest financing agreement with healthcare royalty

Thousand oaks, calif.--( business wire )--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, has entered into a royalty interest financing agreement totaling $31 million with healthcare royalty (hcrx) for ebvallo™ in europe and other territories covered by atara's commercialization agreement with pierre fabre.
ATRA Ratings Summary
ATRA Quant Ranking